Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series

Table 13 Modification of MC dosage in 12 Italian fibromyalgia patients after 3 and 12 months of treatment

Patient: therapy regimen	N = 12
	After 3 months of MC therapy		After 12 months of MC therapy
	THC (mg)	CBD (mg)	THC (mg)	CBD (mg)
Patient #2: Bedrocan decoction	132		66
Patient #4: Bedrocan oil extract	9		9
Patient #5: Bedrocan decoction	66		49.5
Patient #6: FM1 vaporization	106.8		132
Patient #8: FM1 decoction	53.4		50.4
Patient #11: Bedrocan oil extract	31.2		31.2
Patient #12: Pedanios decoction	52.8		52.8
Patient #13: Bedrocan decoction	46.2		46.2
Patient #14: Bedrocan oil extract	8.55		8.58
Patient #15: FM1 decoction	27.6		16.8
Median	49.5		47.85
IQR	53.25		41.25
Mean	53.4		46.2
± SD	40		36.1
Patient #16: Bediol vaporization	28.35	36	28.35	36
Patient #17: Bediol oil extract	1.95	1.95	2.1	1.8

MC medical cannabis, THC Δ-9-tetrahydrocannabinol, CBD cannabidiol, N number of patients, IQR interquartile range, ± plus/minus, SD standard deviation. The table shows the quantity of THC and CBD used in a cohort of 12 patients with fibromyalgia syndrome treated with medical cannabis for at least 12 months at an Italian pain clinic. In the first column, you can see the quantity of MC used after a 3-month therapy, the column on the right shows the quantity of medical cannabis used by those same patients after 12 months MC treatment

ISSN: 2522-5782